Medicine logistics in emerging markets: Southeast Asia
Add bookmark
As growth in developed markets stagnates somewhat, many in the pharmaceutical industry aspire to access the populations in need of better medicine access within emerging markets.
Emerging markets are defined as countries developing in prosperity and likely to achieve higher income. Around 70% of the world’s population live within these markets.
Many of these regions express a strong demand for better access to medicines and health solutions with millions of vaccine preventable deaths being caused due to inadequate supply.
Medicines in southeast Asia
Southeast Asia is experiencing a rise in its number of clinical trials. The lower running cost for clinical trials are attractive to drug manufacturers as they seek to reduce R&D costs. Deloitte expects this factor to only drive the region’s level of clinical trials.
ASEAN (The Association of Southeast Asian Nations) countries are indeed increasing in significance, however these regions do boast varying levels of infrastructure, medical spend and process development.
Download this infographic to explore the key elements impacting pharmaceutical supply chains running through southeast Asia.
Stay tuned for parts two and three of this infographic series looking at Africa and Latin America.
